ATPW
VRTX icon

Ashton Thomas Private Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Buy
2,556
+53
+2% +$24.7K 0.03% 498
2025
Q4 		$1.13M Buy
2,503
+89
+4% +$38.4K 0.03% 458
2025
Q3 		$945K Buy
2,414
+292
+14% +$122K 0.02% 478
2025
Q2 		$945K Sell
2,122
-220
-9% -$101K 0.03% 428
2025
Q1 		$1.14M Buy
2,342
+255
+12% +$119K 0.04% 356
2024
Q4 		$840K Sell
2,087
-204
-9% -$94.6K 0.03% 418
2024
Q3 		$1.07M Sell
2,291
-48
-2% -$23.1K 0.06% 303
2024
Q2 		$1.1M Buy
2,339
+93
+4% +$40.4K 0.06% 294
2024
Q1 		$939K Buy
2,246
+300
+15% +$127K 0.05% 309
2023
Q4 		$792K Buy
1,946
+1,043
+116% +$385K 0.05% 335
2023
Q3 		$314K Buy
903
+11
+1% +$3.85K 0.02% 469
2023
Q2 		$314K Buy
892
+24
+3% +$8.09K 0.02% 472
2023
Q1 		$273K Sell
868
-61
-7% -$18.3K 0.02% 431
2022
Q4 		$268K Buy
929
+56
+6% +$17.1K 0.03% 414
2022
Q3 		$253K Sell
873
-71
-8% -$20.4K 0.03% 410
2022
Q2 		$266K Buy
944
+55
+6% +$14.7K 0.03% 396
2022
Q1 		$232K Buy
+889
New +$211K 0.02% 441

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ashton Thomas Private Wealth's VRTX Position: Q1 2026 in Review

Ashton Thomas Private Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q1 2026, buying an estimated $24.7K and bringing the position to 2,556 shares worth $1.14M. The position accounts for 0.03% of the portfolio, ranked #498.

Ashton Thomas Private Wealth first reported a position in VRTX in Q1 2022 and has held it in 17 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Ashton Thomas Private Wealth held 2,556 shares of Vertex Pharmaceuticals worth $1.14M as of Q1 2026.
  • Ashton Thomas Private Wealth bought 53 Vertex Pharmaceuticals shares in Q1 2026, an estimated $24.7K.
  • Vertex Pharmaceuticals made up 0.03% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #498 holding.
  • Ashton Thomas Private Wealth first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.